0001437749-24-000900.txt : 20240108
0001437749-24-000900.hdr.sgml : 20240108
20240108183318
ACCESSION NUMBER: 0001437749-24-000900
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240105
FILED AS OF DATE: 20240108
DATE AS OF CHANGE: 20240108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Charney Laurence N
CENTRAL INDEX KEY: 0001407451
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32639
FILM NUMBER: 24521367
MAIL ADDRESS:
STREET 1: MARVEL ENTERTAINMENT, INC.
STREET 2: 417 FIFTH AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TG THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001001316
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 363898269
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
BUSINESS PHONE: (212) 554-4484
MAIL ADDRESS:
STREET 1: 2 GANSEVOORT STREET, 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
FORMER COMPANY:
FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030310
FORMER COMPANY:
FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC
DATE OF NAME CHANGE: 20000330
FORMER COMPANY:
FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19960703
4
1
rdgdoc.xml
FORM 4
X0508
4
2024-01-05
0001001316
TG THERAPEUTICS, INC.
TGTX
0001407451
Charney Laurence N
3020 CARRINGTON MILL BLVD, SUITE 475
MORRISVILLE
NC
27560
1
0
Common Stock
2024-01-05
4
S
0
17500
19.03
D
237229
D
In connection with the vesting of 58,732 shares on January 4, 2024, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Charney's income tax obligations. Mr. Charney had no discretion with respect to such sale, which was transacted in accordance with the Company's corporate policies regarding the vesting of restricted stock.
Reflects the weighted average sale price. The range of prices for the shares sold was $19.01 to $19.06. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
Includes shares of restricted Common Stock, which vest over various time periods.
/s/ Laurence N. Charney
2024-01-08